Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-03

AUTHORS

G. Emilien, J.-M. Maloteaux, G. Emilion

ABSTRACT

β-Adrenoceptors are members of a large family of hormone and neurotransmitter receptors that initiate their biological function by coupling to GTP-binding regulatory proteins. β-Adrenoceptors can be subdivided into two main subgroups, designated β1 and β2. Atypical β-adrenoceptors or β3-adrenoceptors, which are present on adipocytes, have been demonstrated pharmacologically. Their function in adipose tissue is currently being investigated.β2-Adrenoceptor agonists have played a key role in the treatment of asthma for some 30 years, being used for the relief and prophylaxis of symptoms. There is, however, no evidence that tolerance to the bronchodilator or anti-bronchoconstrictor effects of these drugs is responsible for the deleterious effects reported with the regular use of bronchodilators.In neuropsychiatry, β-adrenoceptor antagonists have been used for the treatment of acute stress reactions and generalised anxiety, essential tremor and prophylaxis of migraine. In general, they are effective in anxiety disorders if the somatic symptoms are not extreme. For prophylactic treatment of migraine, β-adrenoceptor antagonists such as propranolol, metoprolol, nadolol and atenolol are the drugs of first choice.In cardiology, β-adrenoceptor antagonists are an important class for the treatment of high blood pressure, arrhythmias and angina pectoris, and for prevention of myocardial infarction. With chronic treatment, they reduce mortality in hypertension and prolong survival in patients with coronary heart disease. More... »

PAGES

389-404

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050399

DOI

http://dx.doi.org/10.1007/s002280050399

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042256952

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9551698


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anxiety Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wyeth Ayerst Research, European CR. and D Department, 80 Avenue du Pr\u00e9sident Wilson, Puteaux-92031, Paris La D\u00e9fense, France, FR", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wyeth Ayerst Research, European CR. and D Department, 80 Avenue du Pr\u00e9sident Wilson, Puteaux-92031, Paris La D\u00e9fense, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Emilien", 
        "givenName": "G.", 
        "id": "sg:person.01150666744.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150666744.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory of Pharmacology and Department of Neurology, Universit\u00e9 Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, Belgium, BE", 
          "id": "http://www.grid.ac/institutes/grid.48769.34", 
          "name": [
            "Laboratory of Pharmacology and Department of Neurology, Universit\u00e9 Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, Belgium, BE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maloteaux", 
        "givenName": "J.-M.", 
        "id": "sg:person.01304744241.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304744241.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory of Pharmacology and Department of Neurology, Universit\u00e9 Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, Belgium, BE", 
          "id": "http://www.grid.ac/institutes/grid.48769.34", 
          "name": [
            "Laboratory of Pharmacology and Department of Neurology, Universit\u00e9 Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, Belgium, BE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Emilion", 
        "givenName": "G.", 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-03", 
    "datePublishedReg": "1998-03-01", 
    "description": "Abstract\u03b2-Adrenoceptors are members of a large family of hormone and neurotransmitter receptors that initiate their biological function by coupling to GTP-binding regulatory proteins. \u03b2-Adrenoceptors can be subdivided into two main subgroups, designated \u03b21 and \u03b22. Atypical \u03b2-adrenoceptors or \u03b23-adrenoceptors, which are present on adipocytes, have been demonstrated pharmacologically. Their function in adipose tissue is currently being investigated.\u03b22-Adrenoceptor agonists have played a key role in the treatment of asthma for some 30 years, being used for the relief and prophylaxis of symptoms. There is, however, no evidence that tolerance to the bronchodilator or anti-bronchoconstrictor effects of these drugs is responsible for the deleterious effects reported with the regular use of bronchodilators.In neuropsychiatry, \u03b2-adrenoceptor antagonists have been used for the treatment of acute stress reactions and generalised anxiety, essential tremor and prophylaxis of migraine. In general, they are effective in anxiety disorders if the somatic symptoms are not extreme. For prophylactic treatment of migraine, \u03b2-adrenoceptor antagonists such as propranolol, metoprolol, nadolol and atenolol are the drugs of first choice.In cardiology, \u03b2-adrenoceptor antagonists are an important class for the treatment of high blood pressure, arrhythmias and angina pectoris, and for prevention of myocardial infarction. With chronic treatment, they reduce mortality in hypertension and prolong survival in patients with coronary heart disease.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002280050399", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "53"
      }
    ], 
    "keywords": [
      "\u03b2-adrenoceptor antagonists", 
      "\u03b2-adrenoceptors", 
      "prophylaxis of symptoms", 
      "anti-bronchoconstrictor effects", 
      "prophylaxis of migraine", 
      "atypical \u03b2-adrenoceptors", 
      "high blood pressure", 
      "coronary heart disease", 
      "treatment of asthma", 
      "\u03b22-adrenoceptor agonists", 
      "\u03b2-adrenoceptor agonists", 
      "current therapeutic uses", 
      "acute stress reactions", 
      "blood pressure", 
      "angina pectoris", 
      "chronic treatment", 
      "prolong survival", 
      "prophylactic treatment", 
      "myocardial infarction", 
      "heart disease", 
      "neurotransmitter receptors", 
      "adipose tissue", 
      "essential tremor", 
      "somatic symptoms", 
      "Abstract\u03b2-Adrenoceptors", 
      "antagonist", 
      "anxiety disorders", 
      "first choice", 
      "regular use", 
      "generalised anxiety", 
      "therapeutic uses", 
      "prophylaxis", 
      "bronchodilators", 
      "treatment", 
      "migraine", 
      "agonists", 
      "symptoms", 
      "deleterious effects", 
      "stress reactions", 
      "main subgroups", 
      "drugs", 
      "pectoris", 
      "hypertension", 
      "asthma", 
      "infarction", 
      "patients", 
      "arrhythmias", 
      "propranolol", 
      "mortality", 
      "regulatory proteins", 
      "nadolol", 
      "disease", 
      "metoprolol", 
      "cardiology", 
      "hormone", 
      "atenolol", 
      "prevention", 
      "receptors", 
      "tremor", 
      "biological functions", 
      "disorders", 
      "key role", 
      "survival", 
      "adipocytes", 
      "neuropsychiatry", 
      "subgroups", 
      "tissue", 
      "relief", 
      "\u03b21", 
      "anxiety", 
      "effect", 
      "years", 
      "\u03b22", 
      "large family", 
      "evidence", 
      "function", 
      "protein", 
      "role", 
      "GTP", 
      "tolerance", 
      "pressure", 
      "use", 
      "family", 
      "members", 
      "potential", 
      "choice", 
      "uses", 
      "reaction", 
      "class", 
      "important class"
    ], 
    "name": "Current therapeutic uses and potential of \u03b2-adrenoceptor agonists and antagonists", 
    "pagination": "389-404", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042256952"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050399"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9551698"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050399", 
      "https://app.dimensions.ai/details/publication/pub.1042256952"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_297.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002280050399"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050399'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050399'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050399'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050399'


 

This table displays all metadata directly associated to this object as RDF triples.

191 TRIPLES      20 PREDICATES      122 URIs      114 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050399 schema:about N3fde18b19ced40c6be7fd1b01bb6ba03
2 N54e3ad29af4e4c96ab66f61dda9075b9
3 N5d88008462b84fbc9d4c217e27d33ecc
4 N7dd6f86d165c4663bc59de4e052da7ee
5 N83b60d4f63e04a43af62690c82691c3f
6 Ne16b191e79394a3f9e7d4ff5ef438f57
7 anzsrc-for:11
8 anzsrc-for:1102
9 schema:author Ne25ce54d0e454db185bf3ad5cd581207
10 schema:datePublished 1998-03
11 schema:datePublishedReg 1998-03-01
12 schema:description Abstractβ-Adrenoceptors are members of a large family of hormone and neurotransmitter receptors that initiate their biological function by coupling to GTP-binding regulatory proteins. β-Adrenoceptors can be subdivided into two main subgroups, designated β1 and β2. Atypical β-adrenoceptors or β3-adrenoceptors, which are present on adipocytes, have been demonstrated pharmacologically. Their function in adipose tissue is currently being investigated.β2-Adrenoceptor agonists have played a key role in the treatment of asthma for some 30 years, being used for the relief and prophylaxis of symptoms. There is, however, no evidence that tolerance to the bronchodilator or anti-bronchoconstrictor effects of these drugs is responsible for the deleterious effects reported with the regular use of bronchodilators.In neuropsychiatry, β-adrenoceptor antagonists have been used for the treatment of acute stress reactions and generalised anxiety, essential tremor and prophylaxis of migraine. In general, they are effective in anxiety disorders if the somatic symptoms are not extreme. For prophylactic treatment of migraine, β-adrenoceptor antagonists such as propranolol, metoprolol, nadolol and atenolol are the drugs of first choice.In cardiology, β-adrenoceptor antagonists are an important class for the treatment of high blood pressure, arrhythmias and angina pectoris, and for prevention of myocardial infarction. With chronic treatment, they reduce mortality in hypertension and prolong survival in patients with coronary heart disease.
13 schema:genre article
14 schema:isAccessibleForFree false
15 schema:isPartOf N143572febf544894920b5c1267523a83
16 N55f1d0f490694cf98d41d4ab7df74228
17 sg:journal.1054337
18 schema:keywords Abstractβ-Adrenoceptors
19 GTP
20 acute stress reactions
21 adipocytes
22 adipose tissue
23 agonists
24 angina pectoris
25 antagonist
26 anti-bronchoconstrictor effects
27 anxiety
28 anxiety disorders
29 arrhythmias
30 asthma
31 atenolol
32 atypical β-adrenoceptors
33 biological functions
34 blood pressure
35 bronchodilators
36 cardiology
37 choice
38 chronic treatment
39 class
40 coronary heart disease
41 current therapeutic uses
42 deleterious effects
43 disease
44 disorders
45 drugs
46 effect
47 essential tremor
48 evidence
49 family
50 first choice
51 function
52 generalised anxiety
53 heart disease
54 high blood pressure
55 hormone
56 hypertension
57 important class
58 infarction
59 key role
60 large family
61 main subgroups
62 members
63 metoprolol
64 migraine
65 mortality
66 myocardial infarction
67 nadolol
68 neuropsychiatry
69 neurotransmitter receptors
70 patients
71 pectoris
72 potential
73 pressure
74 prevention
75 prolong survival
76 prophylactic treatment
77 prophylaxis
78 prophylaxis of migraine
79 prophylaxis of symptoms
80 propranolol
81 protein
82 reaction
83 receptors
84 regular use
85 regulatory proteins
86 relief
87 role
88 somatic symptoms
89 stress reactions
90 subgroups
91 survival
92 symptoms
93 therapeutic uses
94 tissue
95 tolerance
96 treatment
97 treatment of asthma
98 tremor
99 use
100 uses
101 years
102 β-adrenoceptor agonists
103 β-adrenoceptor antagonists
104 β-adrenoceptors
105 β1
106 β2
107 β2-adrenoceptor agonists
108 schema:name Current therapeutic uses and potential of β-adrenoceptor agonists and antagonists
109 schema:pagination 389-404
110 schema:productId N96f05578127a4cfe9ebea06a3a367d4a
111 Nbd863d8300634fd59ae0808015488f77
112 Nd58e3a93f394460b9b5d7000614d95fa
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042256952
114 https://doi.org/10.1007/s002280050399
115 schema:sdDatePublished 2022-10-01T06:30
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher Nae003a85942f4502a9d9a38930b2fc98
118 schema:url https://doi.org/10.1007/s002280050399
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N143572febf544894920b5c1267523a83 schema:issueNumber 6
123 rdf:type schema:PublicationIssue
124 N33a151b8734644c085e353c6108f0f67 rdf:first N6f4859d920cf40a8ab11bf639d2a1eb2
125 rdf:rest rdf:nil
126 N3fde18b19ced40c6be7fd1b01bb6ba03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 N54e3ad29af4e4c96ab66f61dda9075b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Asthma
131 rdf:type schema:DefinedTerm
132 N55f1d0f490694cf98d41d4ab7df74228 schema:volumeNumber 53
133 rdf:type schema:PublicationVolume
134 N5d88008462b84fbc9d4c217e27d33ecc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adrenergic beta-Antagonists
136 rdf:type schema:DefinedTerm
137 N6f4859d920cf40a8ab11bf639d2a1eb2 schema:affiliation grid-institutes:grid.48769.34
138 schema:familyName Emilion
139 schema:givenName G.
140 rdf:type schema:Person
141 N7dd6f86d165c4663bc59de4e052da7ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Anxiety Disorders
143 rdf:type schema:DefinedTerm
144 N7e8eba808635472085234ab6134bb9f0 rdf:first sg:person.01304744241.36
145 rdf:rest N33a151b8734644c085e353c6108f0f67
146 N83b60d4f63e04a43af62690c82691c3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adrenergic beta-Agonists
148 rdf:type schema:DefinedTerm
149 N96f05578127a4cfe9ebea06a3a367d4a schema:name doi
150 schema:value 10.1007/s002280050399
151 rdf:type schema:PropertyValue
152 Nae003a85942f4502a9d9a38930b2fc98 schema:name Springer Nature - SN SciGraph project
153 rdf:type schema:Organization
154 Nbd863d8300634fd59ae0808015488f77 schema:name pubmed_id
155 schema:value 9551698
156 rdf:type schema:PropertyValue
157 Nd58e3a93f394460b9b5d7000614d95fa schema:name dimensions_id
158 schema:value pub.1042256952
159 rdf:type schema:PropertyValue
160 Ne16b191e79394a3f9e7d4ff5ef438f57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Heart Diseases
162 rdf:type schema:DefinedTerm
163 Ne25ce54d0e454db185bf3ad5cd581207 rdf:first sg:person.01150666744.25
164 rdf:rest N7e8eba808635472085234ab6134bb9f0
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
169 schema:name Cardiorespiratory Medicine and Haematology
170 rdf:type schema:DefinedTerm
171 sg:journal.1054337 schema:issn 0031-6970
172 1432-1041
173 schema:name European Journal of Clinical Pharmacology
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01150666744.25 schema:affiliation grid-institutes:None
177 schema:familyName Emilien
178 schema:givenName G.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150666744.25
180 rdf:type schema:Person
181 sg:person.01304744241.36 schema:affiliation grid-institutes:grid.48769.34
182 schema:familyName Maloteaux
183 schema:givenName J.-M.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304744241.36
185 rdf:type schema:Person
186 grid-institutes:None schema:alternateName Wyeth Ayerst Research, European CR. and D Department, 80 Avenue du Président Wilson, Puteaux-92031, Paris La Défense, France, FR
187 schema:name Wyeth Ayerst Research, European CR. and D Department, 80 Avenue du Président Wilson, Puteaux-92031, Paris La Défense, France, FR
188 rdf:type schema:Organization
189 grid-institutes:grid.48769.34 schema:alternateName Laboratory of Pharmacology and Department of Neurology, Université Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, Belgium, BE
190 schema:name Laboratory of Pharmacology and Department of Neurology, Université Catholique de Louvain and Cliniques Universitaires Saint Luc, B-1200 Brussels, Belgium, BE
191 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...